Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.
President and CEO Christopher Simon said the company delivered adjusted earnings of $1.29 per share in the quarter, up 4% from a year earlier
For fiscal 2026, Haemonetics reported revenue of $1.3 billion and adjusted earnings of $4.96 per share, with Simon citing higher adjusted margins and stronger free cash flow despite $153 million of non-recurring revenue impacts from portfolio transitions. “Our performance reflects the strength of our core platforms, with Plasma and TEG driving momentum, margin expansion, and reinforcing our leadership in attractive end markets,” Simon said. Plasma Growth Leads Core Momentum Plasma revenue was $130 million in the fourth quarter, up 3% reported and 13% organically excluding CSL, as Haemonetics annualized the final effects of the discontinued CSL U.S. disposable supply agreement. Full-year Plasma revenue was $524 million, down 2% reported but up 20% organically excluding CSL, above the company’s revised guidance range of 17% to 19%.
Simon said Plasma benefited from market fundamentals including resilient immunoglobulin demand and expansion in global plasma collections. He said Haemonetics’ share of U.S. plasma collections grew in the high single digits in both the quarter and the full year, while Europe posted double-digit growth. The company also highlighted U.S.